Grown Rogue International (GRUSF) Non Operating Investment Income (2011 - 2023)
Grown Rogue International (GRUSF) recorded quarterly Non Operating Investment Income of -$64360.0 in Q1 2023, down 118.15% quarter-over-quarter from $354690.0 in Q2 2022, and up 61.65% on a YoY basis from -$39815.5 in Q1 2022.
Grown Rogue International (GRUSF) Non Operating Investment Income (2011 - 2023) Analysis & Trends
Grown Rogue International's Non Operating Investment Income history runs 10 years deep, the most recent figure standing at -$64360.0 for Q1 2023.
- In Q1 2023, Non Operating Investment Income rose 61.65% year-over-year to -$64360.0; the TTM figure through Jan 2023 stood at $219865.0 (up 191.6% YoY), while the FY2022 annual figure was $333777.0, up 1029.69% from the prior year.
- Non Operating Investment Income was -$64360.0 for Q1 2023 at Grown Rogue International, down from $354690.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $354690.0 in Q2 2022 to a low of -$627287.0 in Q2 2020.
- Historically, Non Operating Investment Income has averaged $7106.9 across 4 years, with a median of $73924.3 in 2020.
- Biggest YoY gain for Non Operating Investment Income was 140.38% in 2021; the steepest drop was 937.2% in 2021.
- A 4-year view of Non Operating Investment Income shows it stood at $294740.0 in 2020, then plunged by 66.97% to $97339.0 in 2021, then jumped by 264.39% to $354690.0 in 2022, then plunged by 118.15% to -$64360.0 in 2023.
- The last three Non Operating Investment Income figures came in at -$64360.0 (Q1 2023), $354690.0 (Q2 2022), and -$167804.0 (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Grown Rogue International | - | - | 3.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2023 | -64,360.00 |
| Jan 31, 2023 | -64,360.00 |
| Apr 30, 2022 | 354,690.00 |
| Apr 30, 2022 | 354,690.00 |
| Jan 31, 2022 | -167,804.00 |
| Jan 31, 2022 | -167,804.00 |
| Oct 31, 2021 | 97,339.00 |
| Oct 31, 2021 | 97,339.00 |
| Jul 31, 2021 | -422,867.00 |
| Jul 31, 2021 | -422,867.00 |
| Apr 30, 2021 | 253,300.00 |
| Apr 30, 2021 | 253,300.00 |
| Jan 31, 2021 | 302,808.00 |
| Jan 31, 2021 | 302,808.00 |
| Oct 31, 2020 | 294,740.00 |
| Oct 31, 2020 | 294,740.00 |
| Jul 31, 2020 | 50,509.51 |
| Jul 31, 2020 | 50,509.51 |
| Apr 30, 2020 | -627,287.00 |
| Apr 30, 2020 | -627,287.00 |